OncRef

Clinical Trial: NCT03456063

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Hoffmann-La Roche
Information Provided By:Hoffmann-La Roche
Last Update Posted:2026-10-09

Study Overview

Brief Summary

This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label adjuvant/postoperative atezolizumab or best supportive care and monitoring.

Official Title

A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Conditions

Non-Small-Cell Lung

Intervention / Treatment

  • Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
  • Drug: Placebo Comparator
  • Drug: Nab-paclitaxel
  • Drug: Pemetrexed
  • Drug: Carboplatin
  • Drug: Cisplatin
  • Drug: Gemcitabine

Other Study ID Numbers

  • GO40241
  • 2023-504209-35-00
  • 2023

Start Date (Actual)

2018-04-24

Primary Completion Date (Actual)

2025-10-01

Study Completion Date (Actual)

2025-12-31

Enrollment (Actual)

453

Study Type

Interventional

Phase

Phase 3